To Assess Safety of Fixed Dose Combination of Dapagliflozin and Saxagliptin in Type 2 Diabetes Mellitus Patients
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 196 participants.
Also called NCT04445714
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 196 participants
- Sponsor
- Registry
-
NCT04445714
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- India
- Registry status
- Completed
Technical summary
Registry record NCT04445714. Allocation not applicable; no masking; primary purpose treatment. Start 2021-04-07 (actual); primary completion 2023-03-14 (actual). Results posted on 2024-11-12.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- To Assess Safety of Fixed Dose Combination of Dapagliflozin and Saxagliptin in Type 2 Diabetes Mellitus Patients
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- dapagliflozin and saxagliptin
- Lead sponsor
- AstraZeneca
Record details
- Record id
cardio:ct-nct04445714- Content hash
73513951f0e7e651bc55d9ba7d80c1abe5b7df16f67da3e4effada946fcd9b02